Correcting the QT interval for changes in HR in pre-clinical drug development

Area of Science:

• Pharmacology
• Cardiovascular Safety
• Pre-clinical Drug Development

Background:

• Drug-induced QT interval prolongation is a critical safety concern, potentially causing fatal arrhythmias.
• Existing correction formulas for QT interval are not suitable for animal models in pre-clinical studies.
• Accurate assessment of cardiovascular side effects is essential for drug candidate safety.

Purpose of the Study:

• To evaluate and compare proposed models for assessing drug-induced QT interval prolongation in canine telemetry data.
• To introduce a novel approach combining heart rate correlation and predictive performance for model evaluation.
• To validate model performance using training and testing datasets, including positive and negative controls.

Main Methods:

• Utilized telemetry data from Labrador dogs for analysis.
• Subdivided data into training and test sets for parameter estimation and performance evaluation.
• Employed a PRESS statistic for model performance assessment and analyzed models with treated animals.

Main Results:

• Most evaluated models demonstrated strong performance in eliminating heart rate correlation.
• Models showed reasonable predictive capabilities for QT interval prolongation.
• The models reliably distinguished between positive and negative control groups.

Conclusions:

• The developed models effectively address QT interval prolongation in pre-clinical canine studies.
• Further validation with additional compounds and species is recommended to generalize findings.
• These models enhance the accuracy of cardiovascular safety assessments in early drug development.